Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) EBIT: 2019-2025

Historic EBIT for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$315.3 million.

  • Revolution Medicines' EBIT fell 79.42% to -$315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 58.77%. This contributed to the annual value of -$689.5 million for FY2024, which is 41.53% down from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' EBIT is -$315.3 million, which was down 19.10% from -$264.7 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' EBIT peaked at -$37.4 million during Q1 2021, and registered a low of -$315.3 million during Q3 2025.
  • Moreover, its 3-year median value for EBIT was -$175.7 million (2024), whereas its average is -$181.6 million.
  • Data for Revolution Medicines' EBIT shows a maximum YoY slumped of 191.67% (in 2023) over the last 5 years.
  • Revolution Medicines' EBIT (Quarterly) stood at -$52.9 million in 2021, then decreased by 16.62% to -$61.7 million in 2022, then slumped by 191.67% to -$180.0 million in 2023, then dropped by 20.18% to -$216.3 million in 2024, then tumbled by 79.42% to -$315.3 million in 2025.
  • Its EBIT was -$315.3 million in Q3 2025, compared to -$264.7 million in Q2 2025 and -$240.8 million in Q1 2025.